NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:
The average of price targets set by Wall Street analysts indicates a potential upside of 228.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Arvinas (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The mean of analysts' price targets for Arvinas (ARVN) points to a 235.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Arvinas, Inc. ARVN reported worse-than-expected fourth-quarter sales results on Tuesday.
Arvinas, Inc. (NASDAQ:ARVN ) Q4 2024 Earnings Conference Call February 11, 2025 8:00 AM ET Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - President and Chief Executive Officer Noah Berkowitz - Chief Medical Officer Angela Cacace - Chief Scientific Officer Andrew Saik - Chief Financial Officer Conference Call Participants Derek Archila - Wells Fargo & Company Jonathan Miller - Evercore ISI Li Watsek - Cantor Fitzgerald Akash Tewari - Jefferies Group LLC Tazeen Ahmad - Bank of America Srikripa Devarakonda - Truist Securities Jeet Mukherjee - BTIG, LLC Bradley Canino - Stifel Financial Corp. Sudan Loganathan - Stephens Inc. Edward Tenthoff - Piper Sandler Companies Ellie Merle - UBS Group AG Paul Choi - Guggenheim Securities Michael Schmidt - Guggenheim Partners, LLC Operator Good day, and thank you for standing by. Welcome to the Arvinas Fourth Quarter 2024 Earnings Conference Call.
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $2.53 per share a year ago.
– Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib that demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor – – Announced the planned initiation of first-line Phase 3 trial evaluating vepdegestrant in combination with Pfizer's novel investigational CDK4 inhibitor atirmociclib and a second-line Phase 3 combination trial evaluating vepdegestrant with a CDK4/6 inhibitor, both planned to begin in 2025 – – Initiated a Phase 1 trial with ARV-102 in patients with Parkinson's disease and announced Phase 1 data in healthy volunteers has been accepted for oral presentation at Alzheimer's Disease/Parkinson's Disease congress – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn.
Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.